Peptide library
IGF-1 LR3
Your guide to this compound.
Dose context
No verified derivative-specific human schedule.
No matched human LR3 regimen was verified. Neither a cell assay nor the mecasermin medicine label establishes a daily LR3 dose or near-muscle injection schedule.
How to read this information
Catalog ranges can describe approved labeling, clinical research or unverified reports. They are not interchangeable and do not select a personal dose.
Half-life
No matched human LR3 elimination half-life was verified. In a rat renal-failure model, LR3 clearance increased. Reduced binding-protein affinity alone does not establish the inherited 20–30 hour human claim.
Species, route and formulation matter. Half-life does not define a safe dosing interval.
Routes and frequency in the catalog
No validated route or schedule recorded.
Storage
No stability study or after-opening limit for a matched product was verified. Formulation, container, temperature and sterility matter; no generic 30-day storage rule is established here.
Generic storage notes cannot establish a beyond-use date or sterility for a particular vial.
Preparation and reconstitution
No validated preparation instructions for a matched product were verified. A concentration calculation cannot establish compatibility of diluent, sterility or shelf life.